432 related articles for article (PubMed ID: 12399437)
1. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.
Farilla L; Hui H; Bertolotto C; Kang E; Bulotta A; Di Mario U; Perfetti R
Endocrinology; 2002 Nov; 143(11):4397-408. PubMed ID: 12399437
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.
Farilla L; Bulotta A; Hirshberg B; Li Calzi S; Khoury N; Noushmehr H; Bertolotto C; Di Mario U; Harlan DM; Perfetti R
Endocrinology; 2003 Dec; 144(12):5149-58. PubMed ID: 12960095
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.
Perfetti R; Zhou J; Doyle ME; Egan JM
Endocrinology; 2000 Dec; 141(12):4600-5. PubMed ID: 11108273
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
Pospisilik JA; Martin J; Doty T; Ehses JA; Pamir N; Lynn FC; Piteau S; Demuth HU; McIntosh CH; Pederson RA
Diabetes; 2003 Mar; 52(3):741-50. PubMed ID: 12606516
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 stimulates insulin secretion by a Ca2+-independent mechanism in Zucker diabetic fatty rat islets of Langerhans.
Sreenan SK; Mittal AA; Dralyuk F; Pugh WL; Polonsky KS; Roe MW
Metabolism; 2000 Dec; 49(12):1579-87. PubMed ID: 11145120
[TBL] [Abstract][Full Text] [Related]
6. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
Tourrel C; Bailbe D; Lacorne M; Meile MJ; Kergoat M; Portha B
Diabetes; 2002 May; 51(5):1443-52. PubMed ID: 11978641
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.
Tourrel C; Bailbé D; Meile MJ; Kergoat M; Portha B
Diabetes; 2001 Jul; 50(7):1562-70. PubMed ID: 11423477
[TBL] [Abstract][Full Text] [Related]
8. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.
Scrocchi LA; Hill ME; Saleh J; Perkins B; Drucker DJ
Diabetes; 2000 Sep; 49(9):1552-60. PubMed ID: 10969840
[TBL] [Abstract][Full Text] [Related]
9. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.
Prigeon RL; Quddusi S; Paty B; D'Alessio DA
Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E701-7. PubMed ID: 12773303
[TBL] [Abstract][Full Text] [Related]
10. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects.
Hui H; Farilla L; Merkel P; Perfetti R
Eur J Endocrinol; 2002 Jun; 146(6):863-9. PubMed ID: 12039708
[TBL] [Abstract][Full Text] [Related]
11. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
12. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
13. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.
Toft-Nielson M; Madsbad S; Holst JJ
Diabetes; 1996 May; 45(5):552-6. PubMed ID: 8621002
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
[TBL] [Abstract][Full Text] [Related]
15. Total parenteral nutrition-stimulated activity of inducible nitric oxide synthase in rat pancreatic islets is suppressed by glucagon-like peptide-1.
Salehi A; Ekelund M; Lundquist I
Horm Metab Res; 2003 Jan; 35(1):48-54. PubMed ID: 12669271
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
Pørksen N; Grøfte B; Nyholm B; Holst JJ; Pincus SM; Veldhuis JD; Schmitz O; Butler PC
Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
[TBL] [Abstract][Full Text] [Related]
17. Bioactive GLP-1 in gut, receptor expression in pancreas, and insulin response to GLP-1 in diabetes-prone rats.
Valverde I; Wang GS; Burghardt K; Kauri LM; Redondo A; Acitores A; Villanueva-Peñacarrillo ML; Courtois P; Sener A; Cancelas J; Malaisse WJ; Scott FW
Endocrine; 2004 Feb; 23(1):77-84. PubMed ID: 15034199
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Li Y; Hansotia T; Yusta B; Ris F; Halban PA; Drucker DJ
J Biol Chem; 2003 Jan; 278(1):471-8. PubMed ID: 12409292
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway.
Hui H; Nourparvar A; Zhao X; Perfetti R
Endocrinology; 2003 Apr; 144(4):1444-55. PubMed ID: 12639928
[TBL] [Abstract][Full Text] [Related]
20. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
